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Abstract
Background: IgG4-related disease is a recently described pathologic entity. This is the case of a patient with
nephrotic syndrome and lymphadenopathy due to IgG4-related disease. Such a kidney involvement is quite
peculiar and has only been described a few times recently. Renal biopsy showed a glomerular involvement
with membranous glomerulonephritis in association with a tubulo-interstitial nephropathy. Moreover, the
patient was not suffering from pancreatitis.
Case presentation: The patient is a middle-aged man of Moroccan origin. He has developed recurrent episodes of
diffuse lymphadenopathies, renal failure and nephrotic syndrome. Renal biopsies showed membranous
glomerulonephritis.
Discussion and conclusion: The diagnostic approach of this atypical presentation is discussed in this case report as
well as diagnostic criteria, therapeutic strategies, biomarkers and pathophysiology of IgG4-related disease. IgG4-related
membranous glomerulonephritis is a well-established cause of membranous glomerulonephritis. It must be sought after
in every patient with a previous diagnosis of IgG4-related disease and in every patient with this histological finding on
renal biopsy. Corticoids are still the first-line treatment of IgG4-related disease. New therapeutic strategies are needed to
avoid glucocorticoids long term side-effects. Interestingly, the patient was prescribed cyclophosphamide in addition to
glucocorticoids for an immune thrombocytopenia. This treatment had a very good impact on his IgG4-related disease.
Keywords: IgG4-related disease, IgG4-related kidney disease, Lymphadenopathy, Membranous glomerulonephritis,
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Background
IgG4-related disease (IgG4-RD) was first described 50 years
ago as a pancreatitis with hypergammaglobulinemia and
called autoimmune pancreatitis (AIP). The immuno-
globulins involved in this AIP were thereafter characterized
as belonging to the IgG4 subclass. Multisystemic involve-
ment of the disease was noticed only in 2003 and the name
IgG4-RD finally chosen to designate this pathology. All
denominations previously used such as “IgG4 syndrome”
or “IgG4-related sclerosing disease were subsequently
abandoned. Moreover, new denominations were established
for each organ involved i.e. “IgG4-related kidney disease”
(IgG4-RKD) for kidney involvement. Therefore, several
diseases named before the knowledge of their belonging to
the IgG4-RD entity had to be renamed. For example,
“IgG4-related pancreatitis” is now the correct name for AIP,
as is “IgG4-related dacryoadenitis and sialadenitis” the
correct name for Mikulicz syndrome [1, 2].
IgG4-RD is more common in middle-aged men and
can involve every organ. Tumefactive lesions are charac-
teristic of the disease with pseudotumoral swelling often
being its first clinical manifestation. Organ dysfunction,
imaging or biopsic findings can also reveal IgG4-RD.
The histological pattern of lesions is fibro-inflammatory
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with a lymphoplasmocytic infiltrate enriched with
IgG4+ plasma cells and storiform pattern of fibrosis.
Obliterative phlebitis and eosinophilic infiltration are
also commonly observed. The degree of fibrosis
depends on the tissue involved and increases with
time. Marked fibrosis is often described in IgG4-
related retroperitoneal fibrosis (previously called
Ormond’s disease) and in IgG4-related thyroid disease
(previously Riedel’s thyroiditis). Pancreatitis is the
most common manifestation of IgG4-RD and is often
associated with lymphadenopathy, salivary glands and
kidney involvement. IgG4-RD without pancreatitis is
much less common [1, 3].
Case presentation
Patient’s clinical history, explorations and treatment
(Table 1)
A 40-year old male patient of Moroccan origin was
admitted in 2012 for diffuse lymphadenopathy con-
firmed with ultrasound. Blood tests revealed renal insuf-
ficiency (serum creatinine: 1.6 mg/dL, eGFR: 48 ml/min/
1.73 m2), low serum C3 and C4 levels and hypergamma-
globulinemia (4250 mg/dL with oligoclonal banding).
Anti-nuclear antibodies (ANA) were positive at 1/640.
Anti-dsDNA were negative. Urine tests showed proteinuria
(444 mg/L). A thoraco-abdominal computed tomography
and positron-emission tomography/computed tomography
(PET/CT) were performed. The images were compatible
with a lymphoproliferative disorder. Heterogeneous uptake
was also noticed in kidneys. Lymph node biopsy was per-
formed and ruled out a hematologic malignancy. Immuno-
histochemistry showed more than 10 IgG4+ plasma cells per
high powered field (HPF) of biopsy sample with more than
40% of IgG+ plasma cells being IgG4+ (Fig. 1). Serum IgG4
level was then measured at 2790 mg/dL (N < 201 mg/dL).
This episode was not the first in patient’s medical history.
In 2004, the patient had been admitted for lower-limb
edemas and diffuse lymphadenopathy. Renal insufficiency
(serum creatinine: 3.51 mg/dL, eGFR: 24 ml/min/1.73 m2),
low serum C3 and C4 levels and hypergammaglobulinemia
(4590 mg/dL) had already been found. Urine tests showed
high proteinuria (13800 mg/l) with hypoalbuminemia
characteristic of a nephrotic syndrome. Renal ultrasound
showed diffuse kidney enlargement. PET/CT showed the
same results as the one performed in 2012. A lymphoprolif-
erative disorder was excluded by whole skeleton X-Ray,
bone marrow and lymph node biopsy. A renal biopsy was
then performed and showed membranous glomeruloneph-
ritis (MGN) with IgG and C3d deposits (Fig. 2). Severe
tubulo-interstitial nephropathy (TIN) with lymphoplasmo-
cytic infiltrate (CD20+, CD3+, CD5+) was associated. Sec-
ondary causes of MGN were rejected by appropriate tests.
ANA were negative at the time. The proposed diagnosis
was a dysimmune state of unknown origin with secondary
MGN and reactive lymphadenopathy. Treatment with
glucocorticoids (GC) was started with an excellent clinical
and biological response.
In 2005, a cutaneous rash appeared on the left arm and
was biopsied, showing IgG and C3d deposits. GC were
stopped in 2006 given the recovery of renal function.
A few months later, the patient started to complain
of pain, redness and swelling in small joints of the
feet and hands.
In 2008, the first relapse occurred with the same
clinical picture that in 2004 (nephrotic syndrome and
lymphadenopathy). Full assessment was repeated
yielding similar results except for renal biopsy: MGN
with IgG and C3d deposits was found again but
chronic interstitial nephropathy replaced the severe
TIN. Indeed, a mononuclear infiltrate was present in the
interstitium without clear sign of tubular involvement. A
severe thrombocytopenia (platelets: 8.103/mm3) developed
a few weeks later with anti-dsDNA found on blood sample
(1/80). Thrombocytopenia was refractory to perfusion
of immunoglobulins, GC and cyclophosphamide (CYP).
Plasmapheresis and splenectomy were then performed.
CYP was next continued for 6 cycles (500 mg/cycle)
with good efficacy. Relapsing thrombocytopenia was
successfully treated by additional regiments of immu-
noglobulins and GC. The last cycle of CYP was com-
pleted at the end of 2008. Thereafter, the patient
experienced a long period without any problem until
the next hospitalization in 2012.
In 2012, a renal biopsy was not performed again despite a
new relapse of nephrotic syndrome; indeed, the 2008 biopsy
had led to a macroscopic urinary hemorrhage which had
required embolization. MGN was assessed again and anti-
phospholipase A2 receptor (PLA2R) antibodies were
negative. Diagnosis of IgG4-RD was finally made on the
basis of the lymph node biopsy, with IgG4-related general-
ized lymphadenopathy and IgG4-related MGN (associated
with IgG4-related TIN in 2004). The patient was given GC
again at high dose (methylprednisolone 96 mg daily) for 1
month followed by a progressive decrease of the dose.
Rituximab use was discussed in 2013, due to a new relapse
in spite of maintenance low dose GC therapy and develop-
ment of side effects; unfortunately, the patient failed to
obtain the reimbursement and the medication could not be
given in this context. For now, the patient is well stabi-
lized with low dose GC. Rituximab in compassionate
use could be reconsidered in case of a new relapse.
Figure 3 shows the evolution of various biological
markers and serum creatinine during 2013.
Discussion
Discussion about patient’s diagnosis
This atypical presentation of a rare pathology (i.e. the
patient never experienced any episode of pancreatitis)
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Table 1 Main laboratory work-up, imaging and histology studies from 2004 to 2012
Year Investigations Results
2004 Laboratory Work-up
Blood tests Serum creatinine: 3.51 mg/dL, eGFR: 24 ml/min/1.73 m2, low serum C3 and C4 levels,
hypergammaglobulinemia (4590 mg/dL), hypoalbuminemia, negative ANA.
Urine tests Proteinuria (13800 mg/l).
Imaging studies
Kidney ultrasound Diffuse kidney enlargement.
Abdominal MRI Infracentimetric lombo-aortic lymphadenopathies and kidney enlargement.
PET/CT Sub and super diaphragmatic hypermetabolic lymphadenopathies compatible with
lymphoproliferative disorder associated with heterogeneous fixation in kidneys.
Whole skeleton X-Ray No lesion.
Histology studies
Bone marrow biopsy Suspicion of myelodysplastic syndrome.
Lymph node biopsy Reactive lymphoid hyperplasia.
Renal biopsy MGN with IgG and C3d deposits associated with severe TIN and lymphoplasmocytic
infiltrate.
2005 Histology studies
Skin biopsy IgG and C3d deposits.
2008 Laboratory Work-up
Blood tests Serum creatinine: 1.55 mg/dL, eGFR: 51 ml/min/1.73 m2, low serum C3 and C4 levels,
hypergammaglobulinemia (3460 mg/dl), ANA (1/80) characterized as anti-dsDNA,
thrombocytopenia.
Urine tests Proteinuria (6081 g/l).
Imaging studies
Abdominal CT Iliac and aortic supra-centimetric lymphadenopathies.
PET/CT Sub and super diaphragmatic hypermetabolic lymphadenopathies in progression
compared to 2004.
Whole skeleton X-Ray No lesion.
Histology studies
Bone marrow biopsy Reactive lymphoid hyperplasia of bone marrow.
Lymph node biopsy Reactive lymphoid hyperplasia.
Renal biopsy MGN with IgG and C3d deposits associated with chronic interstitial nephropathy
(mononuclear infiltrate) without clear sign of tubular involvement.
2012 Laboratory Work-up
Blood tests Serum creatinine: 1.6 mg/dL, eGFR: 48 ml/min/1.73 m2, low serum C3 and C4 levels,
hypergammaglobulinemia (4250 mg/dL) with oligoclonal banding, ANA (1/640),
Anti-dsDNA negative, IgG4 (2790 mg/dL), negative PLA2R antibodies test.
Urine tests Proteinuria (444 mg/l).
Imaging studies
Thoraco-abdominal CT Sub and super diaphragmatic supracentimetric lymphadenopathies.
PET/CT Sub and super diaphragmatic hypermetabolic lymphadenopathies in progression
compared to 2008.
Histology studies
Lymph node biopsy IgG4-related lymphadenopathy (IgG4+/IgG+ cells > 40% and >10 IgG4+
plasma cells per HPF).
Legend: ANA anti-nuclear antibodies, CT computed tomography, HPF high powered field, MGN membranous glomerulonephritis, MRI magnetic
resonance imaging, PET/CT positron-emission tomography/computed tomography, PLA2R anti-phospholipase A2 receptor, TIN tubulo-interstitial
nephropathy
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made difficult the diagnosis of IgG4-RD. Moreover,
IgG4-RD was not well known at the time of the first
symptoms in 2004 and PLA2R antibodies were not
available in daily practice at that time.
First of all, hematologic malignancies had to be excluded
in the presence of lymphadenopathy and biological abnor-
malities. Moreover, a higher risk of developing lymphoma
or neoplasia is highly suspected in IgG4-RD patients [4].
Other systemic diseases such as Sjögren’s syndrome,
sarcoidosis and especially systemic lupus erythematous
(SLE) were also part of the differential diagnoses. A
diagnosis of SLE with associated immune MGN (lupus
“full-house” deposits were not found on renal biopsy) and
reactive lymphadenopathy had been proposed in 2008 and
maintained until 2012 in view of the presence of anti-
dsDNA, thrombocytopenia, arthritis and history of
cutaneous rash. Other entities occasionally associated with
high serum IgG4 level or with IgG4+ plasma cells on
biopsy samples were also ruled out (i.e. granulomatosis
with polyangiitis (GPA), Castleman’s disease or McDuffie
hypocomplementemic urticarial vasculitis [4]).
IgG4-RD is considered as definite in this case because
all three comprehensive diagnostic criteria are met: diffuse
swelling in lymph nodes, elevated serum IgG4 concentra-
tion ≥ 135 mg/dL (2790 mg/dL in 2012) and lymph node
infiltration of IgG4 + plasma cells with ratio of IgG4+/IgG
+ cells > 40% and >10 IgG4+ plasma cells per HPF [5].
MGN are responsible for 30% of adult nephrotic syn-
dromes. Eighty percent of MGN are idiopathic whereas
the other 20% are caused by various pathologies which
we searched for such as infections, cancers and systemic
diseases. Circulating antibodies to the PLA2R (which is
a transmembrane protein located on podocytes) are
found in 70% of idiopathic membranous glomeruloneph-
ritis (IMGN). These antibodies are of IgG4 subclass but
high serum IgG4 levels are not encountered in IMGN.
The observation of glomerular deposits of PLA2R anti-
bodies on biopsy seems to be more sensitive than their
detection in serum. However, this could not be done
here giving the absence of a recent renal biopsy [3, 6].
Kidney involvement in IgG4-RD or IgG4-RKD occurs
in approximately 15% of IgG4-RD patients. It has the
remarkable property to result in two well distinct types
of lesions: first, TIN which is most commonly encoun-
tered and second, glomerulopathy. Pyelitis have also
been described. Glomerular involvement is very rare (7%
of IgG4-RKD). Lymphoplasmocytic infiltrate and stori-
form pattern of fibrosis need not be present for its diag-
nosis. MGN is the only glomerular lesion that can be
reliably attributed to IgG4-RD. However, other forms of
Fig. 1 Lymph node biopsy: histopathological diagnostic criteria for IgG4-RD. 1) Highlighting of plasma cells with CD38 × 20: brown cells are
positive for CD38 which indicates most cells in the lymph node are plasma cells. Eosinophilic infiltration is also present. 2) Highlighting of IgG4+
plasma cells × 40. Brown cells are IgG4+ plasma cells. There are more than 10 IgG4+ plasma cells on the picture that represents a high powered
field. 3) Highlighting of IgG+ plasma cells × 20. 4) Highlighting of IgG4+ plasma cells × 20. More than 40% of IgG+ plasma cells are estimated to
be IgG4+
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Fig. 2 Renal biopsy: membranous glomerulonephritis and highlighting of IgG and C3d immune complexes’ deposits. 1) Hematoxylin Eosin × 4: red
arrows show abnormal glomeruli. Green arrow shows normal glomerulus (nevertheless capsular fibrosis is observed). Purple arrow shows normal tubuli.
2) Highlighting of IgG’s deposits × 20: red arrows surround pathological glomerulus. IgG’s deposits in this glomerulus show more contrast than
surrounding tissues. 3) Highlighting of C3d immune complexes’ deposits × 20: red arrows point to pathological glomerulus which shows more
contrast than surrounding tissues because of C3d immune complexes’ deposits. 4) Immersion M + × 100: red arrow shows membranous
glomerulonephritis’s typical thickening of glomerular basement membrane. This thickening is due to reaction against IgG and C3d’s deposits
Fig. 3 Graphical representation of main biological parameters evolution in 2013. At the beginning of the year, patient experienced a new relapse of his
IgG4-RD with impairment in renal function (increase in serum creatinine) and an increase in proteinuria. A lowering of serum complement level is noticed
as well as increased IgG and IgG4 levels at that time. Induction GC therapy started in march and one notices from that moment on a diminution of
IgG-IgG4 level as well as an increase of serum complement level while renal function improved (normalization of serum creatinine). Around July, one sees
a new increase in IgG and IgG4 levels which is consistent with dose reduction in GC therapy. New impairment in renal function was avoided this time by
increasing daily dose of GC. MP =methylprednisolone; qd = daily; qod = every other day
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glomerulopathy such as mesangioproliferative glome-
rulonephritis, IgA nephropathy and membranoprolifera-
tive glomerulonephritis have also been described by
Saeki et al. [7]. Usually, glomerular lesions coexist with
TIN as in our patient’s first renal biopsy. Isolated glom-
erular involvement in IgG4-RKD is uncommon (none of
the biopsies studied by Saeki et al. [7] and in four of the
nine biopsies studied by Alexander et al. [8]). Unfortu-
nately, in our case IgG subclass could not be determined
retrospectively on the renal biopsies of 2004 and 2008
because of insufficient material. However, anti-PLA2R
antibodies were negative in the blood which makes
IMGN less likely and points towards IgG4-related glo-
merulonephritis. This is supported by the good response
to GC, the associated TIN in the first renal biopsy, the
documentation of IgG4-RD in lymph nodes and very
high serum IgG4 levels [2, 3, 7–10]. Jindal et al. [11]
have described a similar case report of IgG4-related
MGN diagnosed through nephrotic syndrome and
lymphadenopathy. In that case, an AIP was associated
(which is more usual) and end-stage renal disease with
need for dialysis could not be avoided despite GC and
rituximab [11].
Specific diagnostic criteria exist for IgG4-RKD [12]. They
were used for our patient and confirmed definite IgG4-
RKD although further analyses could not be performed on
kidney biopsy to assess the presence of IgG4+ plasma cells.
Thus IgG4-related generalized lymphadenopathy and IgG4-
related kidney disease with MGN and TIN are definite in
this case report according to such criteria. Skin and joint
involvement would have needed further investigations to be
confirmed. Thrombocytopenia has never been reported
before such a manifestation of IgG4-RD. Its etiology in this
case report actually remains unclear.
Discussion about treatment, follow-up and pathophysiology
of IgG4-RD
All patients with active IgG4-RD and a subset of asymp-
tomatic patients require treatment, sometimes urgently.
GC are currently the main first-line treatment with
initial good clinical and biological response, especially
when a low degree of fibrosis is present. However,
relapses are very common as seen in this case report
and maintenance GC is often required after induction
therapy. Patients who relapse for the first time after
successful induction should be inducted again by GC.
Introduction of steroid-sparing immunosuppressive
agents should be considered for following relapses due
to the frequency of side effects associated with long term
GC therapy [13]. Mycophenolate mofetil, methotrexate
or azathioprine have shown some efficacy in IgG4-
related pancreatitis [1, 14]. Rituximab is one of the most
promising treatment of relapsing IgG4-related diseases.
Rituximab is an anti-CD20 chimeric antibody that acts
by depleting CD20 positive B-lymphocytes. Good
response has been seen even without initial or concomi-
tant GC therapy and it allowed to discontinue GC in
patients with steroid dependence in several published
cases. Serum IgG4 level is also lowered by this treat-
ment. Clinical and biological response to rituximab is
maintained even after B cell reconstitution [1, 3, 15].
However, in the case reported by Jindal et al. [11], renal
function did not improve after rituximab therapy per-
haps because its late introduction. Further investigations
are needed to assess the exact position and optimal
regimen of rituximab, in IgG4-RKD [11].
It is interesting to note that the patient received CYP
in 2008 for immune thrombocytopenia. This treatment
was followed by 3 years without any manifestation of the
IgG4-RD, in the absence of maintenance GC. CYP was
also given with GC to a patient with IgG4-related TIN
in Australia, and similarly allowed clinical and radio-
logical remission as well as stabilization of renal failure
[14]. Alexander et al. [8] have described a good response
of proteinuria in one patient with IgG4-related MGN
treated by prednisolone and CYP. More experience with
CYP is required to confirm its effectiveness in IgG4-RD.
IgG4-RD follow-up is based on biological markers such
as serum CH50, C3c, C4, IgG and IgG4 values. In case of
relapsing IgG4-RD, a lowering of serum complement level
is classically noticed (especially in IgG4-RKD) as well as
increased IgG and IgG4 levels, as shown in Fig. 3 [2].
However, recent studies showed that these markers are
poor predictors of the need for additional treatment. More
attention should be paid to clinical manifestations [3].
PET/CT has a valuable role in mapping lesions, staging
extent of the disease and guiding biopsy. Some studies
showed that it could also be useful in monitoring response
to treatment and identifying disease relapse earlier than
other imaging techniques [4].
IgG4-RD pathophysiology is not completely under-
stood yet. Excess of T helper 2 (Th2) cells and regulatory
T (Treg) cells has been described in involved organs.
This could explain fibrosis (since transforming growth
factor-beta is secreted by Treg) and increased produc-
tion of IgG4 (because cytokines secreted by Th2 and
Treg stimulate IgG4 class switch). Excess of Th2 can
also explain IgE excess and hyper eosinophilia [1, 16].
This immune imbalance could be due to abnormal reac-
tion against pathogenic agents (i.e. Helicobacter pylori)
or to commensals belonging to normal microbiota with
continuous presentation of antigen by B cells. This could
explain clinical improvement observed following B-cell
depletion by rituximab [3]. In genetic studies, higher
prevalence of HLA-DRB10405 and HLA-DQB10401 has
been reported in Japanese patients with IgG4-RD [1].
An important question remains: are IgG4 pathogenic or
not in IgG4-RD? The recent discovery of serum IgG4-
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negative IgG4-RD raises questions about the causative role
of the IgG4 molecule [2]. ANA are frequently found in
IgG4-RD patients as seen in this case report and are
suspected to be pathogenic but do not belong to the IgG4
subclass [17]. Moreover, IgG4 is a relatively non-
inflammatory antibody because it undergoes heavy-chain
exchange leading to monovalent but bispecific antibody
with reduced ability to crosslink antigens and form
immune complexes. The amino acid sequence in its CH2
domain also limits IgG4 interaction with C1q and Fcγ
receptors [3, 18]. Nevertheless, recent studies show the
capacity of IgG4 to form aggregates which can cause
inflammatory lesions in the absence of antigen [19]. So,
IgG4-RD can be considered either as an allergic disease
where IgG4 are only a marker of Th2 and Treg excess in
tissues [1] or can be seen as an immune disorder where
IgG4 could play by itself in the pathology [7].
Conclusions
We have described the rare history of a patient with
MGN secondary to IgG4-RD without pancreatitis.
Several mechanisms still remain to be discovered
about IgG4-RD such as the role of IgG4 antibodies and
even the nature of the pathology itself. However, it is
now a better defined pathology with comprehensive
diagnostic criteria and a large number of cases are now
described.
GC therapy is a potent initial treatment in IgG4-RD,
avoiding end-stage renal disease in IgG4-RKD for ex-
ample. It must be initiated before occurrence of fibrosis
for better response. This emphasizes the importance of
early diagnosis. However, resistance and side effects to GC
finally occur and steroid-sparing immunosuppressive
agents have to be considered. Rituximab seems to be a
promising treatment. CYP also proved to be a very good
therapy in our case and in others: these case observations
would justify the design of controlled clinical trials to
evaluate its effectiveness in IgG4-RD.
IgG4-RD follow-up can be based on biological markers
such as serum CH50, C3c, C4, IgG and IgG4 values, but
they are imperfect predictors. PET/CT could be more
reliable for the follow-up.
The differential diagnosis of IgG4-related generalized
lymphadenopathy from lymphoproliferative disorders
(especially malignant lymphoma) is very difficult. PET/
CT is not helpful in this indication and lymph node bi-
opsies are crucial to exclude hematologic malignancies.
Diagnosis of IgG4-RD does not dispense to perform new
lymph nodes biopsies when relapse occurs. Indeed,
higher risk of developing lymphoma in IgG4-RD patients
is suspected.
Kidney involvement is rare without associated pan-
creatitis. Glomerular involvement (mainly MGN) is even
more uncommon especially without associated TIN.
Further studies of MGN secondary to IgG4-RD will be
welcome to improve our current knowledge of this
disease. Nevertheless IgG4-related MGN appears already
to be a well-established cause of MGN which must be
sought after in every patient with a previous diagnosis of
IgG4-RD but also in every patient with MGN found on
renal biopsy.
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